As the vaginal walls become thinner and drier and lose some of the folds that allow them to stretch, some women never notice any symptoms. Others may experience a burning sensation, a feeling of dryness, some itching, or a thin, watery discharge. While symptoms of vaginal dryness and atrophy can be very bothersome, the good news is that effective treatment options are available. These include different forms of low-dose estrogens applied directly to the vagina, as well as non-hormonal treatments. In the present study an attempt was made to formulate robust vaginal tablets suitable for scale up manufacturing and commercial use.
Preliminary trials were planned using different grades of Hypromellose which showed good results with respect to flow property and compressibility but a variation in release profile form tablet o tablet. Seeing this later it was decided to formulate the tablet using Low viscosity polymer for better drug release and uniformity. Marketed formulation, falls within the USP specification. From the results of present investigation, it can be concluded that the tablet dosage form was successfully formulated and it has matched the target dissolution profile with specific time point with innovators patent and the final optimized formulation has shown the expected result for all the evaluation parameters.Keywords: Vaginal walls, Estrogens, Hypromellose, Drug release, vaginal atrophy.